Emily Greengard1, Yael P Mosse2, Xiaowei Liu3, Charles G Minard4, Joel M Reid5, Stephan Voss6, Keith Wilner7, Elizabeth Fox2, Frank Balis2, Susan M Blaney4, Peter C Adamson2, Brenda J Weigel8. 1. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. emilyg@umn.edu. 2. St Jude Children's Research Hospital, Memphis, TN, USA. 3. Children's Oncology Group, Monrovia, CA, USA. 4. Baylor College of Medicine, Houston, TX, USA. 5. Mayo Clinic, Rochester, MN, USA. 6. Dana Farber Cancer Institute, Boston, MA, USA. 7. Pfizer, Inc, Bentonville, AR, USA. 8. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Abstract
PURPOSE: This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL. METHODS: Pediatric patients with treatment refractory solid tumors or ALCL were eligible. Using a 3 + 3 design, crizotinib was escalated in three dose levels: 165, 215, or 280 mg/m2/dose BID. In Part A, patients received crizotinib oral solution (OS) in combination with topotecan and cyclophosphamide (topo/cyclo); in Part B, crizotinib OS was administered with vincristine and doxorubicin (vcr/dox). In Parts C and D, patients received topo/cyclo in combination with either crizotinib-formulated capsules (FC) or microspheres (cMS), respectively. Crizotinib pharmacokinetic evaluation was required. RESULTS: Forty-four eligible patients were enrolled, 39 were evaluable for toxicity. Parts A and B were terminated due to concerns regarding palatability and tolerability of the OS. In Part C, crizotinib, FC 215 mg/m2/dose BID, in combination with topo/cyclo was tolerated. In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS. Pharmacokinetics of crizotinib in combination with chemotherapy was similar to single-agent crizotinib and exposures were not formulation dependent. CONCLUSIONS: The RP2D of crizotinib FCs in combination with cyclophosphamide and topotecan was 215 mg/m2/dose BID. The oral solution of crizotinib was not palatable in this patient population. Crizotinib cMS was palatable; however, patients experienced increased toxicity that was not explained by the relative bioavailability or exposure and warrants further investigation. CLINICAL TRIAL REGISTRY: The trial is registered as NCT01606878 at Clinicaltrials.gov.
PURPOSE: This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL. METHODS: Pediatric patients with treatment refractory solid tumors or ALCL were eligible. Using a 3 + 3 design, crizotinib was escalated in three dose levels: 165, 215, or 280 mg/m2/dose BID. In Part A, patients received crizotinib oral solution (OS) in combination with topotecan and cyclophosphamide (topo/cyclo); in Part B, crizotinib OS was administered with vincristine and doxorubicin (vcr/dox). In Parts C and D, patients received topo/cyclo in combination with either crizotinib-formulated capsules (FC) or microspheres (cMS), respectively. Crizotinib pharmacokinetic evaluation was required. RESULTS: Forty-four eligible patients were enrolled, 39 were evaluable for toxicity. Parts A and B were terminated due to concerns regarding palatability and tolerability of the OS. In Part C, crizotinib, FC 215 mg/m2/dose BID, in combination with topo/cyclo was tolerated. In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS. Pharmacokinetics of crizotinib in combination with chemotherapy was similar to single-agent crizotinib and exposures were not formulation dependent. CONCLUSIONS: The RP2D of crizotinib FCs in combination with cyclophosphamide and topotecan was 215 mg/m2/dose BID. The oral solution of crizotinib was not palatable in this patient population. Crizotinib cMS was palatable; however, patients experienced increased toxicity that was not explained by the relative bioavailability or exposure and warrants further investigation. CLINICAL TRIAL REGISTRY: The trial is registered as NCT01606878 at Clinicaltrials.gov.
Authors: Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé Journal: Sci Transl Med Date: 2011-11-09 Impact factor: 17.956
Authors: Kateryna Krytska; Hannah T Ryles; Renata Sano; Pichai Raman; Nicole R Infarinato; Theodore D Hansel; Monish R Makena; Michael M Song; C Patrick Reynolds; Yael P Mossé Journal: Clin Cancer Res Date: 2015-10-05 Impact factor: 12.531
Authors: Pasi A Jänne; Alice T Shaw; D Ross Camidge; Giuseppe Giaccone; S Martin Shreeve; Yiyun Tang; Zelanna Goldberg; Jean-François Martini; Huiping Xu; Leonard P James; Benjamin J Solomon Journal: J Thorac Oncol Date: 2016-02-18 Impact factor: 15.609
Authors: Sai-Hong Ignatius Ou; Ramaswamy Govindan; Keith D Eaton; Gregory A Otterson; Martin E Gutierrez; Alain C Mita; Athanassios Argiris; Nicoletta M Brega; Tiziana Usari; Weiwei Tan; Steffan N Ho; Francisco Robert Journal: J Thorac Oncol Date: 2016-09-30 Impact factor: 15.609
Authors: K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn Journal: Br J Cancer Date: 2010-04-27 Impact factor: 7.640
Authors: Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los Journal: Mol Cancer Ther Date: 2007-12 Impact factor: 6.261
Authors: Elizabeth G Gibson; Olivia Campagne; Nicholas S Selvo; Amar Gajjar; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2021-09-29 Impact factor: 3.333
Authors: Tingting Liu; Matthew D Merguerian; Steven P Rowe; Christine A Pratilas; Allen R Chen; Brian H Ladle Journal: Cold Spring Harb Mol Case Stud Date: 2021-08-02